Introduction {#Sec1}
============

Respiratory syncytial virus (RSV) is one of the most common causes of viral lower respiratory tract infection (LRTI) in children worldwide and is associated with considerable morbidity and mortality \[[@CR1]\]. LRTI was the leading cause of infectious disease hospitalizations among infants according to a recent analysis of hospital admissions in the United States (US) \[[@CR2]\]. Globally, LRTI is the leading cause of death among post-neonatal infants (i.e., 28--364 days of age). In 2010, 20.1% of the 2 million global deaths among post-neonatal infants were caused by LRTI; malaria was the second most common cause, accounting for 11.8% of post-neonatal mortality \[[@CR3]\]. The most commonly identified pathogen of LRTI in post-neonatal infants is RSV \[[@CR3]\]. These findings highlight the significance of the malaria parasite *Plasmodium falciparum* and RSV as the two most important pathogen-specific causes of global mortality in this age group \[[@CR3]\]. In addition to severe acute disease, evidence also suggests that children who had severe RSV infection early in life are more likely to develop subsequent wheezing during early childhood \[[@CR4]\] and hyperreactive airways and asthma later in life \[[@CR5]\].

RSV is a typically seasonal virus with outbreaks spanning from late autumn through early spring in temperate climates and throughout the rainy season in tropical climates. RSV is an extremely infectious virus, such that almost all children have contracted RSV by the age of 2 years \[[@CR6]\]. Furthermore, re-infections are frequent because previous infection with RSV does not confer long-term immunity \[[@CR7]\]. RSV disease manifestations in infants range from mild upper respiratory tract infection to respiratory failure. Certain high-risk groups, including premature infants; infants with underlying medical conditions such as chronic lung disease of prematurity (CLDP), also known as bronchopulmonary dysplasia (BPD); hemodynamically significant congenital heart disease (CHD); immunocompromised conditions; and severe neuromuscular disease, are more prone to serious disease due to RSV with higher hospitalization and mortality rates than those without these conditions \[[@CR8], [@CR9]\].

RSV is classified in the *Pneumovirus* genus of the *Paramyxovirida*e family of RNA viruses. RSV is an enveloped virus, containing a negative-sense, single-stranded RNA genome comprising \~15,000 nucleotides that encode 11 viral proteins \[[@CR10]\]. The antigenicity of RSV is determined by two transmembrane glycoproteins. The RSV G glycoprotein is responsible for viral attachment to cells, and the RSV F glycoprotein promotes fusion of viral and cell membranes \[[@CR10], [@CR11]\]. Both the G and F glycoproteins are targets for RSV-neutralizing antibodies. RSV is classified in A and B subgroups, based on antigenic differences in the G protein \[[@CR12]\].

The current goal of RSV vaccine development is the prevention of serious RSV disease in the population at highest risk, i.e., young infants \[[@CR13]\]. In the absence of an effective, curative treatment for RSV infection \[[@CR13]\], disease management is guided by the severity of respiratory distress and primarily involves supportive strategies such as hydration and oxygenation \[[@CR6], [@CR14]\]. An effective vaccine against RSV would be expected to decrease the global health burden and is urgently needed; however, one does not currently exist owing to the complexity and inherent challenges of RSV vaccine development. For example, neonates at risk for developing RSV disease have not been able to mount a strong immune response following administration of vaccines in development. Strategies for vaccinating pregnant women have been proposed with the intent of maternal transfer of anti-RSV antibodies to the fetus \[[@CR13]\]. However, this approach may not provide adequate protection for very premature infants, who may not benefit from immunity afforded by maternal immunization because transplacental transport of antibodies occurs during the third trimester \[[@CR15]\]. Efficacy was not demonstrated in a series of trials in the 1960s that evaluated a formalin-inactivated whole virus RSV vaccine. Ironically, respiratory disease from natural RSV infection was more severe in children who received the experimental vaccine compared with children who did not receive the vaccine \[[@CR16]--[@CR18]\]. Moreover, in 1 trial in which 31 infants 2--7 months of age received ≥1 injection of an experimental antigenic inactivated RSV vaccine, 2 deaths were attributed to the exaggerated clinical course of disease during RSV infection and were deemed to be associated with the vaccine \[[@CR17]\]. Although the biologic cause leading to this phenomenon was never definitively determined, these discouraging results led to a more measured and conservative approach in the development of an RSV vaccine. There are currently a number of vaccine candidates in preclinical or phase I or II clinical development \[[@CR13]\]; however, for the time being, passive immunity is the only means available to help reduce hospitalizations due to severe RSV disease.

The current prophylactic approach is passive immunity with antibodies. The first of such products was a polyclonal immunoglobulin formulation enriched for RSV-neutralizing antibody (RespiGam^®^; MedImmune, LLC, Gaithersburg, MD, USA) that reduced moderate or severe LRTI disease caused by RSV by 72% \[[@CR19]\] and, in 1996, was the first prophylactic agent approved by the US Food and Drug Administration (FDA) for use in high-risk children. However, its use was hampered by the requirement that large volumes of immunoglobulin be administered by intravenous (IV) infusion over several hours on a monthly basis throughout the RSV season. While RespiGam was effective in reducing the incidence of RSV-related hospitalization in both preterm infants and infants with BPD \[[@CR20]\], RespiGam did not significantly reduce the RSV-related hospitalization rate in children with CHD and was associated with increased cyanotic episodes and cardiac-related deaths in children with cyanotic CHD \[[@CR21]\].

Research efforts were then directed toward the development of alternative agents with less complex methods of administration and potentially increased efficacy. The use of RespiGam was discontinued in 2003 following the 1998 approval of palivizumab (Synagis^®^; MedImmune, LLC, Gaithersburg, MD, USA) and the demonstration that a monoclonal antibody could be efficacious against an infectious agent. Compared with the IV administration of RespiGam, palivizumab is administered via an intramuscular (IM) injection. The evolution from polyclonal IV to monoclonal IM injection eliminated concerns for transmission of bloodborne pathogens as well as potential fluid overload. Palivizumab is a humanized monoclonal antibody specific for the antigenic site A on the highly conserved F protein on the surface of RSV. Palivizumab has potent neutralizing and fusion-inhibiting activity against RSV subgroups A and B \[[@CR22]\]. Depending on the patient population, the efficacy of palivizumab ranged from a 39% to 78% reduction in RSV-related hospitalization compared with placebo in the 2 pivotal randomized controlled trials (RCTs) \[[@CR23], [@CR24]\]. Palivizumab was approved by the FDA in 1998 for use in reducing the risk of serious LRTI disease caused by RSV in children at high risk of RSV disease. Populations where efficacy has been established are children with BPD, CHD, and premature infants (≤35 weeks gestational age \[GA\]) \[[@CR23], [@CR24]\]. Prophylaxis with palivizumab begins before the expected start of the RSV season, with additional doses given monthly throughout the season. In its original formulation, palivizumab was supplied as a lyophilized product that required reconstitution with sterile water for IM injection. This process took \~20 min. A liquid formulation of palivizumab was subsequently developed, precluding the need for reconstitution. Bioequivalence between the lyophilized and liquid formulations was demonstrated in children ≤6 months of age with a history of prematurity \[[@CR25]\]. The liquid formulation was first approved in 2004 in the US and is also currently available in Japan; broad global filings and approvals of the liquid preparation are ongoing.

We conducted a timely and comprehensive systematic review of RCTs, open-label non-comparative clinical trials, and prospective observational studies/registries to summarize and describe the existing evidence related to the safety, efficacy, and effectiveness of palivizumab for reducing the risk of serious RSV LRTI disease in high-risk infants and children.

Methods {#Sec2}
=======

Literature Search {#Sec3}
-----------------

We performed a literature search in MEDLINE (via PubMed), Embase, BIOSIS Previews, and Derwent Drug File using the following general terms and limits: "respiratory syncytial virus" AND "palivizumab OR Synagis" AND "premature" AND "congenital heart disease OR bronchopulmonary dysplasia OR chronic lung disease" AND "efficacy OR effect" AND "limits: human, premature/preterm (up to 35 weeks), English, clinical trial OR prospective observational study". Separate literature searches were performed for RCTs and prospective observational studies/registries (see the Appendix in the electronic supplementary material). Published articles and congress abstracts indexed from January 1996 through July 2013 in MEDLINE and from January 1996 through August 2013 in the other databases were searched. References contained in any systematic reviews and meta-analyses found through the literature search were also reviewed to identify additional relevant studies not already captured.

Study Selection {#Sec4}
---------------

All results from the literature search were reviewed at the abstract level by three authors (LKT, GN, CW). Inclusion criteria for the systematic review were studies reporting the primary outcome of the RSV-related hospitalization rate in children at high risk of severe RSV disease who received ≥1 injection of palivizumab at 15 mg/kg. High risk was defined as children with a history of prematurity (≤35 weeks GA) or children with BPD or hemodynamically significant CHD. Retrospective studies, epidemiologic studies, case reports, letters, comments, editorials, reviews, and meta-analyses were excluded from the systematic review. Results from the literature search and cross-referenced publications found from systematic reviews or meta-analyses that appeared to meet these selection criteria were independently reviewed at the full-text level by the same three authors; any disagreements over whether to include a study in the systematic review were resolved by discussion among the authors.

Data Analyses {#Sec5}
-------------

A meta-analysis of the primary outcome of RSV-related hospitalization was conducted for the randomized placebo-controlled trials included in this systematic review. A fixed-effects meta-analysis was used (Mantel--Haenszel method) to assess the odds ratio (OR) of palivizumab compared with placebo using Review Manager Version 5.3 (The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen, Denmark). Because of the heterogeneity of the study populations and methodologic variability among the studies, no formal combined statistical analyses were performed across the other types of studies or for any of the other major outcomes (i.e., RSV hospitalization-related outcomes, drug-related adverse events \[AEs\] and serious adverse events \[SAEs\]). Therefore, we describe the results of the included studies separately.

Statement of Ethics Compliance {#Sec6}
------------------------------

The analysis in this article is based on previously published studies and does not involve any new studies of human subjects performed by any of the authors.

Results {#Sec7}
=======

A total of 347 publications were retrieved from the literature search and reviewed at the abstract level (Fig. [1](#Fig1){ref-type="fig"}); 314 abstracts were rejected for not meeting the selection criteria or for duplicative reporting. Thirty-three publications from the literature search and an additional 14 cross-referenced publications were reviewed at the full-text level, with 26 being rejected after author review for the reasons shown in Fig. [1](#Fig1){ref-type="fig"}. The final 21 publications included in this review originated from 7 RCTs, 4 open-label non-comparative trials, and 8 prospective observational studies or registries, with 3 publications \[[@CR26]--[@CR28]\] reporting results from different time periods or populations of the same registry. The analysis comprises more than 42,000 high-risk infants/children from 34 countries. Characteristics of the studies included in this systematic review are described in Appendix Table A1.Fig. 1Study selection diagram. *Asterisk* indicates three articles reported results on different time periods and subject populations from the same registry. *RSV* Respiratory syncytial virus

Efficacy: Reduction of RSV-Related Hospitalization {#Sec8}
--------------------------------------------------

### Efficacy of Palivizumab in Randomized, Placebo-Controlled Clinical Trials {#Sec9}

Palivizumab administered at 15 mg/kg monthly during the RSV season was initially evaluated as a pre-approval IV formulation in a phase I/II, randomized, double-blind, placebo-controlled trial conducted from 1995 to 1996 in the US \[[@CR29]\]. In this trial, the incidence of RSV-related hospitalization in children ≤24 months of age with BPD or infants ≤6 months of age who were born at ≤35 weeks GA was 10.0% (2/20) with placebo and 0% (0/22) with palivizumab (Table [1](#Tab1){ref-type="table"}).Table 1RSV-associated hospitalizations and related efficacy endpoints in the randomized controlled trialsPopulationStudyStudy drugRSV-associated hospitalizationRSV ICU admissionMechanical ventilationIncidence, *n/N* (%)Relative reduction rate vs. placebo, % (95% CI)*P* value vs. placeboTotal days/100 subjectsDays with increased supplemental oxygen% SubjectsTotal days% SubjectsTotal daysBPD/CLDP or prematuritySubramanian et al. \[[@CR29]\]Placebo2/20 (10.0)NANANANANANAPalivizumab0/22 (0)100NANANANANANANAIMpact-RSV \[[@CR24]\]Placebo53/500 (10.6)62.650.63.012.70.21.7Palivizumab48/1,002 (4.8)55 (38, 72)\<0.00136.4 (*P* \< 0.001)30.3 (*P* \< 0.001)1.3 (*P* = 0.026)13.3 (*P* = 0.023)0.78.4Carbonell-Estrany et al. \[[@CR70]\]Palivizumab62/3,306 (1.9)18.19.5/100 subjects0.66.3/100 subjects0.33.8/100 subjectsMotavizumab46/3,329 (1.4)9.14.1/100 subjects0.32.0/100 subjects0.10.5/100 subjectsBPD/CLDPIMpact-RSV \[[@CR24]\]Placebo34/266 (12.8)NANANANANANAPalivizumab39/496 (7.9)39 (20, 58)0.038NANANANANANACarbonell-Estrany et al. \[[@CR70]\]Palivizumab28/723 (3.9)NANANANANANAMotavizumab22/722 (3.0)NANANANANANAPrematurity (all)Carbonell-Estrany et al. \[[@CR70]\]Palivizumab34/2,583 (1.3)NANANANANANAMotavizumab24/2,607 (0.9)NANANANANANA ≤32 weeks GACarbonell-Estrany et al. \[[@CR70]\]Palivizumab19/1,265 (1.5)NANANANANANAMotavizumab13/1,306 (1.0)NANANANANANATavsu et al. \[[@CR31]\]No prophylaxisProphylaxis year: 10/41 (24.4)\
Following year: 10/41 (24.4)NANANANANANAPalivizumabProphylaxis year: 0/39 (0)\
Following year: 0/39 (0)1000.001NANANANANANA 33--35 weeks GACarbonell-Estrany et al. \[[@CR70]\]Palivizumab15/1,318 (1.1)NANANANANANAMotavizumab11/1,301 (0.8)NANANANANANAMAKI \[[@CR30]\]Placebo11/215 (5.1)NANANANANANAPalivizumab2/214 (0.9)82 (18, 157)0.01NANANANANANA ≤35 weeks GAIMpact-RSV \[[@CR24]\]Placebo19/234 (8.1)NANANANANANAPalivizumab9/506 (1.8)78 (66, 90)\<0.001NANANANANANACHD (all)Cardiac \[[@CR23]\]Placebo63/648 (9.7)129.06583.74612.2354Palivizumab34/639 (5.3)45 (23, 67)0.00357.4 (*P* = 0.003)178 (*P* = 0.014)2.01011.342Feltes et al. \[[@CR71]\]Palivizumab16/612 (2.6)18.919.81.027.50.728.5Motavizumab12/623 (1.9)12.78.50.87.00.38.0 CyanoticCardiac \[[@CR23]\]Placebo7.9NANANANANANAPalivizumab5.6290.285NANANANANANAFeltes et al. \[[@CR71]\]Palivizumab7/319 (2.2)NANANANANANAMotavizumab7/346 (2.0)NANANANANANA AcyanoticCardiac \[[@CR23]\]Placebo11.8NANANANANANAPalivizumab5.0580.003NANANANANANAFeltes et al. \[[@CR71]\]Palivizumab9/293 (3.1)NANANANANANAMotavizumab5/277 (1.8)NANANANANANAAge \<6 monthsCardiac \[[@CR23]\]Placebo12.2NANANANANANAPalivizumab6.051NANANANANANANA 6--12 monthsPlacebo7.3NANANANANANAPalivizumab6.116NANANANANANANA 1--2 yearsPlacebo4.3NANANANANANAPalivizumab1.858NANANANANANANADetailed characteristics of these studies are presented in Appendix Table A1*BPD* Bronchopulmonary dysplasia, *CHD* hemodynamically significant congenital heart disease, *CLDP* chronic lung disease of prematurity, *GA* gestational age, *ICU* intensive care unit, *NA* not available, *RSV* respiratory syncytial virus

Subsequent studies of palivizumab included in this review were performed using the IM injection formulation. The efficacy of palivizumab as measured by the reduction in the RSV-related hospitalization rate was subsequently assessed in two large, randomized, double-blind, placebo-controlled trials \[[@CR23], [@CR24]\].

The IMpact-RSV trial was conducted during a single RSV season from 1996 to 1997 and studied a total of 1,502 children ≤24 months of age with BPD or infants ≤6 months of age who were born prematurely (≤35 weeks GA) in the US, Canada, and the United Kingdom (UK) \[[@CR24]\]. In children who were premature or who had BPD, palivizumab reduced RSV-associated hospitalization by 55%, from an incidence of 10.6% (53/500) in children receiving placebo versus 4.8% (48/1,002) in children receiving palivizumab (Table [1](#Tab1){ref-type="table"}; Fig. [2](#Fig2){ref-type="fig"}). In addition, the reduction of RSV-related hospitalization was observed both in children with BPD (34/266 \[12.8%\] with placebo versus 39/496 \[7.9%\] with palivizumab; 39% relative reduction) and in premature infants without BPD (19/234 \[8.1%\] with placebo versus 9/506 \[1.8%\] with palivizumab; 78% relative reduction; Table [1](#Tab1){ref-type="table"}).Fig. 2RSV-related hospitalization rates in the large randomized controlled trials: **a** IMpact-RSV \[[@CR24]\], **b** Carbonell-Estrany et al. \[[@CR70]\], **c** MAKI \[[@CR30]\], **d** Tavsu et al. \[[@CR31]\], **e** Cardiac \[[@CR23]\], and **f** Feltes et al. \[[@CR71]\] studies. Relative reduction rate compared with placebo is shown as ↓%. *Asterisk* indicates without BPD/CLDP. *BPD* Bronchopulmonary dysplasia, *CHD* hemodynamically significant congenital heart disease, *CLDP* chronic lung disease of prematurity, *GA* gestational age, *mo* months, *RSV* respiratory syncytial virus, *wk* weeks, *y* years

The Cardiac trial was conducted over 4 consecutive seasons from 1998 to 2002 in a total of 1,287 children ≤24 months of age with hemodynamically significant CHD in the US, Canada, Sweden, Germany, France, the UK, and Poland \[[@CR23]\]. In this trial, palivizumab reduced RSV-associated hospitalization by 45% in children with hemodynamically significant CHD from an incidence of 9.7% (63/648) in children receiving placebo versus 5.3% (34/639) in children receiving palivizumab (Table [1](#Tab1){ref-type="table"}; Fig. [2](#Fig2){ref-type="fig"}) \[[@CR23]\]. Although the Cardiac study was not powered for subgroup analyses, there were reductions in RSV-related hospitalization rates in both cyanotic and acyanotic children (Table [1](#Tab1){ref-type="table"}; Fig. [2](#Fig2){ref-type="fig"}).

A recent prospective RCT (ClinicalTrials.gov \#ISRCTN73641710) conducted from 2008 to 2010 in the Netherlands further defined the efficacy of palivizumab in premature infants by GA \[[@CR30]\]. In 429 preterm infants born at 33--35 weeks GA without underlying health conditions, the incidence of RSV-associated hospitalization was reduced by 82%, from an incidence of 5.1% in those receiving placebo (11/215) versus 0.9% in those receiving palivizumab (2/214; *P* = 0.01; Table [1](#Tab1){ref-type="table"}) \[[@CR30]\]. In addition, RSV infection requiring medical attention but not hospitalization was also significantly reduced by 81%, from an incidence of 4.7% in recipients of placebo (10/215) versus 0.9% in recipients of palivizumab (2/214; *P* = 0.02) \[[@CR30]\].

More recently, Tavsu et al. \[[@CR31]\] conducted a study from 2009 to 2011 in 80 infants with a GA of \<32 weeks in Turkey. These infants were randomized to receive prophylaxis with palivizumab (study group, *n* = 39) or no prophylaxis (control group, *n* = 41). The incidence of RSV-related hospitalization was significantly lower in the study group than the control group both in the year of prophylaxis and the following year (0% vs. 24.4% in both years; *P* = 0.001; OR 1.32 \[95% CI, 1.11--1.57\]; Table [1](#Tab1){ref-type="table"}).

Combining the results from these 5 randomized placebo-controlled trials in a meta-analysis of the RSV-related hospitalization rate yielded an overall OR of 0.41 (95% CI, 0.31--0.55) in favor of palivizumab prophylaxis over placebo (*P* \< 0.00001; Fig. [3](#Fig3){ref-type="fig"}).Fig. 3Meta-analysis of RSV-related hospitalization in the randomized, placebo-controlled trials. *M*--*H* Mantel--Haenszel method, *RSV* respiratory syncytial virus

### Efficacy of Palivizumab in Prospective, Open-Label, Non-Comparative Clinical Trials {#Sec10}

During the 1998--1999 RSV season, Abbott Laboratories (now AbbVie) conducted an Expanded Access Trial, which was a phase III and IV, multicenter, single-arm, open-label study to collect additional safety data on palivizumab-prophylaxed infants in countries where palivizumab was not yet available \[[@CR32]\]. The study included preterm children born at ≤35 weeks GA who were ≤6 months old at enrollment, and children with BPD. A total of 565 children were enrolled in 16 countries in Europe, North America, and the Middle East, with 530 completing the study. Fifty-one (65%) of 78 hospitalizations during the study were due to respiratory causes. Among 29 cases tested for RSV, 7 were positive and 22 were negative. When the RSV test positivity rate (24%) was applied to the 22 untested respiratory cases, the estimated RSV hospitalization rate was 2.1% (12/565; Table [2](#Tab2){ref-type="table"}).Table 2RSV-associated hospitalizations and related efficacy endpoints in the open-label non-comparative studiesPopulationStudyRSV-associated hospitalizationRSV ICU admissionMechanical ventilationIncidence, *n/N*(%)Total days/100 subjectsDays with increased supplemental oxygen% Subjects% SubjectsBPD/CLDP, prematurity, or CHDTurti et al. \[[@CR40]\]0/100 (0)NANANANABPD/CLDP or prematurityExpanded Access \[[@CR32]\]12/565 (2.1)NANANANABPD/CLDPLacaze-Masmonteil et al. \[[@CR38]\]First-season exposure: 1/71 (1.4)NANANANASecond-season exposure: 4/63 (6.3)Prematurity 29--32 weeks GAPROTECT \[[@CR39]\]5/285 (1.8)17.6Median 7.5 (range 6.0--9.0)0.70.7 ≤35 weeks GALacaze-Masmonteil et al. \[[@CR38]\]5/134 (3.7)NANANANADetailed characteristics of these studies are presented in Appendix Table A1*BPD* Bronchopulmonary dysplasia, *CLDP* chronic lung disease of prematurity, *GA* gestational age, *ICU* intensive care unit, *NA* not available, *RSV* respiratory syncytial virus

Many guidelines are aligned with the licensed indications of palivizumab and recommend that children with BPD requiring medical intervention at the onset of the RSV season receive prophylaxis up to the age of 24 months at the start of the RSV season (US, UK, Canada, Spain, and Germany) \[[@CR33]--[@CR37]\]. Therefore, some children with severe BPD will receive prophylaxis for more than one RSV season. A multicenter, open-label study was conducted in 7 European countries and Canada in 134 children \<2 years old at risk for serious RSV infection, primarily because of BPD \[[@CR38]\]. Seventy-one subjects without previous palivizumab exposure (mean age 8 months) and 63 subjects exposed to palivizumab during the previous season (mean age 16 months) received prophylaxis with palivizumab during the 1999--2000 RSV season. Five subjects (3.7%) were hospitalized for RSV-related respiratory illness overall, with no differences in incidence observed between the first-season exposure (1 \[1.4%\]) and second-season exposure subjects (4 \[6.3%\]; *P* = 0.187; Table [2](#Tab2){ref-type="table"}) \[[@CR38]\]. This study demonstrated a risk of serious RSV disease persisting beyond the first year of life in children with BPD.

Premature infants, regardless of their GA, are at high risk for serious RSV disease. As the subset of infants born at 29--32 weeks GA without CLDP was not specifically evaluated in the IMpact-RSV study \[[@CR24]\], the PROTECT (Palivizumab RSV Open-label Trial of Effectiveness and Clinical Tolerability) study \[[@CR39]\] was conducted to gather additional data in this patient population. During the 2000--2001 season, 285 subjects were enrolled from 16 European countries and Saudi Arabia. Of 20 (7%) hospitalizations for respiratory-related infections, 5 (1.8%) subjects were hospitalized for RSV-positive LRTI (Table [2](#Tab2){ref-type="table"}). This RSV hospitalization rate is comparable to the incidence observed in the IMpact-RSV study \[[@CR24]\].

Prior to palivizumab approval in the Russian Federation, a multicenter, prospective, open-label, non-comparative clinical study (ClinicalTrials.gov \#NCT01006629) was conducted in high-risk children \[[@CR40]\]. The study included children at high risk of serious RSV disease, defined as infants born at ≤35 weeks GA who were ≤6 months old at enrollment or children ≤24 months old with a clinical diagnosis of BPD and/or hemodynamically significant CHD. One hundred subjects received ≥1 injection of palivizumab during the 2009--2010 RSV season, and 94 completed their dosing schedule. There were no RSV hospitalizations (Table [2](#Tab2){ref-type="table"}) or deaths. Of the seven subjects hospitalized for respiratory/cardiac conditions, six were tested for RSV and all test results were negative.

RSV-Related Hospitalizations in Prospective Observational Studies/Registries {#Sec11}
----------------------------------------------------------------------------

Prospective observational studies and registries provide valuable information regarding the use of palivizumab in routine clinical practice and have accumulated a wealth of real-world information on the clinical effectiveness of RSV immunoprophylaxis with palivizumab. Over 13 years (1999--2011) and across 8 observational studies/registries in Spain, France, Germany, Canada, and the US, RSV-related hospitalization rates for prophylaxed infants/children ranged from 0.8% to 7.6% \[[@CR26], [@CR41]--[@CR46]\] (Table [3](#Tab3){ref-type="table"}). The highest rate (7.6%) was observed in a French registry \[[@CR42]\], whereas the rate ranged from 0.8% to 3.95% in the other observational studies/registries \[[@CR26], [@CR41], [@CR43]--[@CR46]\]. The higher RSV hospitalization rate observed in the French registry may have been driven by enrollment of a very-high-risk population where 88% of subjects in the cohort had a GA ≤32 weeks, 52% were children born before 28 weeks GA, and the rate of BPD was 81%. In comparison, the rate of BPD among children enrolled in the IMpact-RSV study was 50% \[[@CR24], [@CR42]\]. In general, RSV-related hospitalization rates were similar for palivizumab recipients in the observational studies/registries and in the randomized placebo-controlled trials.Table 3RSV-associated hospitalizations and related efficacy endpoints in the prospective observational studies/registriesPopulationStudyRSV-associated hospitalizationRSV ICU admissionMechanical ventilationIncidence, % of *N*Total days, mean ± SDDays with increased supplemental oxygen, mean ± SD% SubjectsTotal days, mean ± SD% SubjectsTotal days, mean ± SDBPD/CLDP or prematurityPedraz et al. \[[@CR45]\]Nonprophylaxed: 13.25 of 1,583Median (IQR), 8 (5, 11)NA2.1NA0.8NAPalivizumab: 3.95 of 1,919Median (IQR), 6 (4, 9) (*P* \< 0.01)0.50.4BPD/CLDPPedraz et al. \[[@CR45]\]Nonprophylaxed: 19.7 of 71NANANANANANAPalivizumab: 5.5 of 217 (*P* \< 0.007)French ATU Program \[[@CR42]\]9.0 of 400NANANANANANAPalivizumab Outcomes Registry \[[@CR41]\]2.40 of 4,329NANANANANANACARESS (2005--2009)^a^ \[[@CR26]\]1.31^b^ of 449NANANANANANAPrematurity ≤28 weeks GAPedraz et al. \[[@CR45]\]Nonprophylaxed: 13.0 of 246NANANANANANAPalivizumab: 5.4 of 739 (*P* \< 0.0001)French ATU Program \[[@CR42]\]5.8 of 258NANANANANANACARESS (2005--2009)^c^ \[[@CR26]\]1.34^b^ of 1,704NANANANANANA 29--32 weeks GAPedraz et al. \[[@CR45]\]Nonprophylaxed: 9.9 of 1,297NANANANANANAPalivizumab: 2.5 of 1,170 (*P* \< 0.0000)French ATU Program \[[@CR42]\]10.4 of 182NANANANANANACARESS (2005--2009)^a^ \[[@CR26]\]1.25^b^ of 1,449NANANANANANA \<32 weeks GAPalivizumab Outcomes Registry \[[@CR41]\]1.84 of 7,786NANANANANANA ≤32 weeks GACanadian Special Access Programme \[[@CR44]\]1.6^b^ of 324NANANANANANACARESS (2006--2011)^a^ \[[@CR28]\]1.5^b^ of 5,1836.7 ± 5.40.5 ± 2.20.31.2 ± 2.70.31.3 ± 2.9 32--35 weeks GAPalivizumab Outcomes Registry \[[@CR41]\]0.83 of 9,294NANANANANANA 33--35 weeks GACARESS (2005--2009)^a^ \[[@CR26]\]0.2^b^ of 588NANANANANANACARESS (2006--2011)^a^ \[[@CR28]\]1.4^b^ of 1,4715.2 ± 5.00.2 ± 0.90.31.3 ± 2.40.30.3 ± 1.8 \<35 weeks GALesnick et al. \[[@CR43]\]1.0 of 2,838NANANANANANA ≤35 weeks GACARESS (2005--2009)^a^ \[[@CR26]\]1.12^b^ of 3,741NANANANANANACARESS (2006--2010)^a^ \[[@CR27]\]1.3^b^ of 4,8807.3 ± 6.90.7 ± 2.90.31.7 ± 3.70.21.0 ± 3.1CHDPalivizumab Outcomes Registry \[[@CR41]\]1.88 of 1,490NANANANANANACARESS (2005--2009)^a^ \[[@CR26]\]1.99^b^ of 508NANANANANANAAll prescribedFrench ATU Program \[[@CR42]\]7.6^c^ of 516NANA1.9NA0.8NACanadian Special Access Programme \[[@CR44]\]2.4^b^ of 444 evaluable5.5 ± 3.8NANANANANALesnick et al. \[[@CR43]\]0.8 of 3,520NANANANANANAGolombek et al. \[[@CR72]\]1.17 of 1,446 overall (3.57 of 224 physician's office setting; 0.93 of 969 home setting)NANANANANANAPalivizumab Outcomes Registry \[[@CR41]\]1.3 of 19,474^d^ evaluableNANANANANANAGerman Palivizumab Registry \[[@CR46]\]1.6^c^ of 9,833 evaluableNANA^c^0.5NA0.1NACARESS (2005--2009)^d^ \[[@CR26]\]1.38^b^ of 5,2868.0 ± 6.80.9 ± 3.1NA2.4 ± 4.5NA2.0 ± 4.1 Congenital airway abnormality/severe neuromuscular diseasePalivizumab Outcomes Registry \[[@CR41]\]2.14 of 1,122NANANANANANA \>35 weeks GA and non-BPD/CHD medical disordersCARESS (2006--2010)^a^ \[[@CR27]\]2.4^b^ of 9527.3 ± 5.81.6 ± 3.60.83.3 ± 5.41.33.6 ± 5.0 \>35 weeks GAPalivizumab Outcomes Registry \[[@CR41]\]1.13 of 2,390NANANANANANA OtherCARESS (2005--2009)^a^ \[[@CR26]\]2.78^b^ of 592NANANANANANADetailed characteristics of these studies are presented in Appendix Table A1. Pedraz et al. 2003 \[[@CR45]\] was a prospective, observational, case-controlled study; all other studies were prospective observational studies/registries. For all studies, results for subgroups with \<100 palivizumab-prophylaxed patients were not reported here because of the small numbers*BPD* bronchopulmonary dysplasia, *CHD* hemodynamically significant congenital heart disease, *CLDP* chronic lung disease of prematurity, *ICU* intensive care unit, *IQR* interquartile range, *GA* gestational age, *NA* not available, *RSV* respiratory syncytial virus^a^Some reported patient populations may overlap^b^RSV hospitalization rate = hospitalization rate × (subjects RSV positive/subjects tested)^c^RSV hospitalization rate = hospitalization rate × (subjects RSV positive/subjects tested) was 8.1% for the French ATU Program \[[@CR42]\] and 2.5% for the German Palivizumab Registry \[[@CR46]\]^d^1,047 subjects were enrolled for \>1 season and were counted as separate enrollments per season enrolled

Secondary Outcomes: RSV Hospitalization-Related Endpoints {#Sec12}
---------------------------------------------------------

Although prophylaxis with palivizumab reduces the incidence of RSV-related hospitalizations, some children still develop breakthrough disease and require hospitalization. Tables [1](#Tab1){ref-type="table"}, [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"} illustrate the effect of palivizumab prophylaxis on RSV hospitalization-related endpoints. These are important surrogate markers of disease severity and include duration of RSV-related hospitalization, intensive care unit (ICU) admission, oxygen supplementation, and mechanical ventilation.

In the IMpact-RSV study, children with BPD or a history of prematurity randomized to receive prophylaxis with palivizumab spent significantly fewer days in the hospital and required fewer days of supplemental oxygen during RSV hospitalization compared with children randomized to receive placebo (all *P* \< 0.001; Table [1](#Tab1){ref-type="table"}) \[[@CR24]\]. The overall requirement for ICU admission and/or mechanical ventilation was low and was influenced by a small number of children with complex underlying disease. Differences in the incidence of and days on mechanical ventilation did not differ significantly between groups \[[@CR24]\].

Children with hemodynamically significant CHD receiving palivizumab prophylaxis also had significantly fewer days of RSV-related hospitalization (*P* = 0.003) and significantly fewer days with increased oxygen requirement compared with children receiving placebo (*P* = 0.014; Table [1](#Tab1){ref-type="table"}) \[[@CR23]\]. Other secondary efficacy endpoints, including incidence and days in the ICU and days on mechanical ventilation were not significant but did exhibit trends favoring palivizumab over placebo.

The results of the RSV hospitalization-related outcomes from the non-comparative trials and observational studies are similar to the results from the RCTs. For example, the percentage of subjects with BPD or prematurity who required mechanical ventilation was 0.7% in the open-label PROTECT trial (Table [2](#Tab2){ref-type="table"}) conducted in 16 European countries and Saudi Arabia \[[@CR39]\] and 0.1--0.8% in 2 observational studies (Table [3](#Tab3){ref-type="table"}) conducted in Spain and the US \[[@CR27], [@CR28], [@CR45]\] compared with 0.3--1.3% in the RCTs (Table [1](#Tab1){ref-type="table"}). In the only observational study to include case controls, there was a statistically significant reduction in RSV hospitalization duration and numerical decreases in the percentage of subjects requiring ICU admission or mechanical ventilation in Spanish subjects who received prophylaxis with palivizumab compared with those who did not receive prophylaxis \[[@CR45]\].

Safety and Immunogenicity {#Sec13}
-------------------------

The safety data for palivizumab was first established in 2,789 infants enrolled in the two registrational randomized placebo-controlled trials (Table [4](#Tab4){ref-type="table"}) \[[@CR23], [@CR24]\]. In the IMpact-RSV trial, there was no difference in the placebo and palivizumab groups in the number of children who had AEs that were judged to be related to the study drug by the blinded investigator (10% vs. 11%) \[[@CR24]\]. Study subjects rarely discontinued prophylaxis due to palivizumab-related AEs (0.3%), and the incidence of related AEs did not differ significantly between the placebo and palivizumab groups. Similar safety findings were demonstrated in the Cardiac study \[[@CR23]\]. The proportion of children with AEs judged by the blinded investigator to be related to the study drug was similar between the placebo and palivizumab groups (6.9% vs. 7.2%). No child had the study drug discontinued for a related AE, and the incidence of related SAEs was low and similar in the placebo and palivizumab groups (0.5% vs. 0%).Table 4Summary of safety in the randomized clinical trialsPopulationStudyStudy drug doseSubjects with ≥1 at least possibly related, %Most commonly reported AEs, %Commonly reported SAEs, %Injection site reaction, %AEs leading to D/C, %Deaths, %AESAEBPD/CLDP, prematurity, or CHDExpanded Access \[[@CR32]\]Palivizumab (*n* = 565)6.9NAFever 1.5%, diarrhea 0.8%, nervousness/irritability 0.8%^a^NA2.3^a^1.90.4Lacaze-Masmonteil et al. \[[@CR38]\]Palivizumab, season 1 (*n* = 71)NA0Infection, injection site reaction, diarrhea 1.4% each^a^Bronchiolitis 5.6%, BPD aggravation 2.8%, vomiting 2.8%1.4^a^00Palivizumab, season 2 (*n* = 63)NA0Fever 3.2%; anorexia, epistaxis, ataxia 1.6% each^a^Bronchiolitis 4.8%, fever 3.2%0^a^00Turti et al. \[[@CR40]\]Palivizumab (*n* = 100)2.00Rhinitis, dermatitis 1.0% eachNANA1.00BPD/CLDP or prematuritySubramanian et al. \[[@CR29]\]Placebo (*n* = 20)15.0NANANANA05.0Palivizumab 15 mg/kg (*n* = 22)23.0NANANANA00IMpact-RSV \[[@CR24]\]Placebo (*n* = 500)10.0NAFever 3.0%, nervousness 2.6%, injection site reaction 1.6%^a^NA1.8NA1.0Palivizumab 15 mg/kg (*n* = 1,002)11.0NAFever 2.8%, nervousness 2.5%, injection site reaction 2.3%^a^NA2.70.30.4Carbonell-Estrany et al. \[[@CR70]\]Palivizumab 15 mg/kg (*n* = 3,298)NANAURTI 30.1%, pyrexia 16.9%, rhinitis 13.5%, otitis media 12.8%, bronchiolitis 9.9%, teething 8.6%, diarrhea 8.5%, respiratory disorder 8.4%, nasal congestion 8.0%, conjunctivitis 7.6%, gastroenteritis 7.1%, bronchitis 6.9%, constipation 6.9%, cough 6.5%, gastroesophageal reflux disease 6.3%, diaper dermatitis 5.8%, vomiting 5.2%, irritability 5.0%NA2.70.30.1PrematurityMAKI \[[@CR30]\]Placebo (*n* = 215)NANANANANANA0Palivizumab 15 mg/kg (*n* = 214)NANANANANANA0CHDCardiac \[[@CR23]\]Placebo (*n* = 648)6.90.5URTI 46.1%, fever 23.9%, conjunctivitis 9.3%, cyanosis 6.9%, infection 2.9%, arrhythmia 1.7%Arrhythmia 0.3%, cyanosis 2.2%2.20^a^4.2Palivizumab 15 mg/kg (*n* = 639)7.20URTI 47.4%, fever 27.1%, conjunctivitis 11.3%, cyanosis 9.1%, infection 5.6%, arrhythmia 3.1%Arrhythmia 0.2%, cyanosis 3.6%3.40^a^3.3Feltes et al. \[[@CR71]\]Palivizumab 15 mg/kg (*n* = 612)8.81.0Pyrexia 29.2%, URTI 28.1%, rhinitis 12.6%, cough 11.6%, otitis media 11.4%, gastroenteritis 10.8%, diarrhea 10.6%, nasopharyngitis 9.5%, vomiting 8.3%, Tetralogy of Fallot 8.2%, bronchitis 7.8%, rhinorrhea 7.4%, ventricular septal defect 6.2%, teething 5.9%, pneumonia 5.9%, blood urea increased 5.6%, nasal congestion 5.4%, constipation 5.1%, viral infection 5.1%, dermatitis diaper 5.1%Tetralogy of Fallot 8.0%, ventricular septal defect 5.9%, pneumonia 3.8%, atrioventricular septal defect 3.6%NA0.21.6Detailed characteristics of these studies are presented in Appendix Table A1. The Tavsu et al. 2014 \[[@CR31]\] trial did not report safety events and was therefore not included in this table*AE* adverse event, *BPD* bronchopulmonary dysplasia, *CHD* congenital heart disease, *CLDP* chronic lung disease of prematurity, *D/C* discontinuation of study drug, *NA* not available, *SAE* serious adverse event, *URTI* upper respiratory tract infection^a^Considered at least possibly related to study drug

Given that palivizumab has been in clinical use for 16 years, follow-up clinical trials, outcome data from several international registries and post-marketing experience are consistent with the initial safety profile. Uncontrolled trial (Table [5](#Tab5){ref-type="table"}) and observational/registry data (Appendix Table A2) presented in this systematic review are consistent with respect to safety findings. Commonly reported AEs from these data include injection site reactions and fever. Across RCTs and open-label non-comparative trials, \<2% of AEs led to study drug discontinuation. In addition, injection site reactions and severe thrombocytopenia (platelet count \<50,000 per microliter) have been voluntarily reported during post-approval use of palivizumab in over 3.2 million seasonal courses of therapy (data on file, AbbVie). As these events are voluntarily reported, their frequency and causal relationship to palivizumab cannot always be reliably estimated \[[@CR22]\].Table 5Summary of safety in the open-label non-comparative studiesPopulationStudyStudy drug doseSubjects with ≥1 at least possibly related, %Most commonly reported AEs, %Commonly reported SAEs, %Injection site reaction, %AEs leading to D/C, %Deaths, %AESAEBPD/CLDP, prematurity, or CHDExpanded Access \[[@CR32]\]Palivizumab (*n* = 565)6.9NAFever 1.5%, diarrhea 0.8%, nervousness/irritability 0.8%^a^NA2.3^a^1.90.4Lacaze-Masmonteil et al. \[[@CR38]\]Palivizumab, season 1 (*n* = 71)NA0Infection, injection site reaction, diarrhea 1.4% each^a^Bronchiolitis 5.6%, BPD aggravation 2.8%, vomiting 2.8%1.4^a^00Palivizumab, season 2 (*n* = 63)NA0Fever 3.2%; anorexia, epistaxis, ataxia 1.6% each^a^Bronchiolitis 4.8%, fever 3.2%0^a^00Turti et al. \[[@CR40]\]Palivizumab (*n* = 100)2.00Rhinitis, dermatitis 1.0% eachNANA1.00PrematurityPROTECT \[[@CR39]\]Palivizumab (*n* = 285)NANAFever, infection, enteritis, bronchiolitis, bronchitis, increased cough, pneumonia, rhinitis, conjunctivitis 0.4% each^a^RSV infection, RSV bronchiolitis, pneumonia, conjunctivitis 0.4% each^a^NA0.70Detailed characteristics of these studies are presented in Appendix Table A1*AE* Adverse event, *BPD* bronchopulmonary dysplasia, *CHD* congenital heart disease, *CLDP* chronic lung disease of prematurity, *D/C* discontinuation of study drug, *NA* not available, *RSV* respiratory syncytial virus, *SAE* serious adverse event, *URTI* upper respiratory tract infection^a^Considered at least possibly related to study drug

SAE reporting was limited in the registries. In the German Palivizumab Registry \[[@CR46]\] conducted from 2002 to 2007, 10 (0.09%) of 10,686 patients had ≥1 SAE considered possibly or probably related to palivizumab administration: dyspnea/cyanosis with or without fever (*n* = 4); skin rash; thrombocytopenia with petechiae; osteomyelitis of the distal femur epiphysis; seizure; transient unresponsiveness; and fever, restlessness, and feeding difficulties (*n* = 1 each). From 2005 to 2009, in the total population of 5,286 subjects enrolled in CARESS \[[@CR26]\], 61 SAEs were reported overall, of which 56 were hospitalizations due to respiratory infection (including 14 from breakthrough RSV infection).

Allergic reactions, including very rare cases of anaphylaxis and anaphylactic shock, have been reported following palivizumab administration in post-marketing settings. In some cases, fatalities have been reported. However, because the AEs identified via post-marketing surveillance are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to palivizumab exposure.

With repeated exposure, there is a theoretical concern that recipients of palivizumab could develop an immune response to the monoclonal antibody. In the IMpact-RSV trial, anti-palivizumab antibodies were assessed before the first and last palivizumab injections and in a randomized manner before the second, third, or fourth injection \[[@CR24]\]. In the placebo and palivizumab groups, titers \>1:40 were detected in 2.8% and 1.2% of subjects, respectively. These elevations generally occurred at single time points and were not associated with low palivizumab concentrations or increased AEs. In a French study conducted to assess the incidence of anti-palivizumab antibodies and clinical AEs in children prophylaxed with palivizumab for a first (no previous palivizumab exposure) versus a second RSV season, similar serum concentrations of palivizumab were observed for both first-season and second-season subjects, and none had a significant anti-palivizumab antibody response, defined as a titer of ≥1:80 occurring at any time during the study \[[@CR38]\].

Discussion {#Sec14}
==========

This systematic review, which assessed results from 7 RCTs, 4 open-label non-comparative trials, and 8 prospective observational studies or registries comprising over 42,000 high-risk infants/children from 34 countries, found that palivizumab has shown consistent efficacy or effectiveness in the reduction of RSV-related hospitalizations in high-risk populations. Prophylactic administration of palivizumab demonstrated an acceptable safety profile in the identified studies. The data presented in this systematic review are important for understanding how palivizumab is currently used in clinical practice as well as the issues that remain of interest to the medical community.

Current Issues in RSV Immunoprophylaxis {#Sec15}
---------------------------------------

Strategies for diminishing the health care burden from RSV infections include appropriate and targeted prophylaxis in children at high risk of severe RSV disease. Palivizumab is widely approved across Europe, US, Canada, Asia, and Latin America; however, in an effort to ensure optimal balance of benefit and cost from this intervention, clinical guidelines are country specific and vary with regard to their recommendations for prophylaxis in premature infants \[[@CR33]--[@CR37], [@CR47]--[@CR49]\]. Compared with term infants, preterm infants have increased susceptibility to severe RSV disease, irrespective of the degree of prematurity, due to interrupted lung development and an immature immune system. Alveolar development is not universally present until 36 weeks GA and continues following birth through 2 years of age \[[@CR50]\]. While the immune systems of term infants are aided by maternal transfer of antibodies across the placenta in the third trimester, preterm infants are born prior to completion of this transfer \[[@CR51]\]. There is general agreement that because of the cost of palivizumab prophylaxis, guidelines should be put in place to ensure cost-effective use in well-defined high-risk populations rather than to arbitrarily restrict RSV prophylaxis from a portion of this vulnerable population. Late-preterm infants account for approximately three quarters of the preterm birth population \[[@CR52]\], and there is evidence that they experience increased morbidity and even higher neonatal mortality compared with near-term or full-term infants \[[@CR52]--[@CR55]\]; however, the cost-effectiveness of passive immunoprophylaxis for all late-preterm infants is questioned. Using risk factors in this population, cost-effectiveness can be improved. Robust, validated, evidence-based risk score models based on defined variables have been developed in Canada and Europe \[[@CR56]--[@CR58]\] to identify the late-preterm infants at the highest risk for RSV-related hospitalization. These RSV risk score models have demonstrated cost-effectiveness; thus, these recommendations have been adopted by international pediatric advisory committees \[[@CR35], [@CR59]--[@CR62]\].

Although immunoprophylaxis with palivizumab has been demonstrated to be effective in decreasing RSV hospitalization in high-risk children, hospitalization is only one of the possible consequences of RSV infection. More research is needed to examine the impact of RSV infection on subsequent morbidity and mortality, to understand the full impact and burden of RSV infections, and to clarify additional health benefits and the value of prophylaxis. There is evidence suggesting that palivizumab is associated with reduced infant all-cause mortality \[[@CR63], [@CR64]\]. In addition, prophylaxis with palivizumab has been associated with a reduction in long-term respiratory morbidity of severe RSV infection, such as recurrent wheeze \[[@CR65], [@CR66]\]. In a placebo-controlled trial in otherwise healthy preterm infants of 33--35 weeks GA, prophylaxis with palivizumab led to a 61% reduction in wheezing days that was maintained beyond the end of therapy and throughout the infants' first year of life (*P* \< 0.05) \[[@CR30]\]. A prospective analysis of clinical trial data in preterm children ≤35 weeks GA reported that palivizumab exposure may decrease the incidence of subsequent asthma-like symptoms \[[@CR65]\] and provide a protective effect on recurrent wheezing in prophylaxed children without a family history of atopy through 24 months compared with matched controls \[[@CR67]\]. Finally, a prospective Japanese study in preterm children born at 33--35 weeks GA found a lower incidence of recurrent wheezing during the first 3 years of life after palivizumab exposure \[[@CR66]\]. When considering the impact of palivizumab on long-term respiratory effects, it is important to note that the majority of the evidence is from non-randomized studies and more research with well-designed RCTs is needed before definitive conclusions can be made.

Data concerning the long-term safety of palivizumab are limited. Considering that early human life is an important period of development, research is needed to evaluate the long-term effects after exposure to palivizumab in early childhood.

The emergence of viral escape mutants in response to administration of a monoclonal antibody such as palivizumab must be considered. Palivizumab binds to antigenic site A, a highly conserved region on the extracellular domain of RSV F, which encompasses amino acids 262--275. Only changes in antigenic site A of the F protein have been demonstrated to confer resistance to palivizumab \[[@CR68]\]. The rate of palivizumab-resistant mutations is low in both immunoprophylaxis-naïve patients (\<1%) \[[@CR68]\] and in patients experiencing breakthrough RSV disease while taking palivizumab (6.3%) \[[@CR22]\]. Palivizumab-resistant variants exhibited a growth disadvantage compared with parental viruses and are therefore unlikely to propagate in the community in the absence of selective pressure from palivizumab exposure. In addition, a review of clinical findings among the children who experienced breakthrough RSV disease while taking palivizumab did not reveal an association between mutations in the RSV F protein gene and RSV disease severity \[[@CR69]\]. However, the clinical impact of transfer or distribution of palivizumab-resistant mutants is not clearly understood.

Limitations {#Sec16}
-----------

There are several limitations of this systematic review that must be considered. Although multiple studies and post-marketing experience involving thousands of high-risk infants indicate that palivizumab reduces overall hospitalization rates due to RSV, it is important to note there are few RCTs and the majority of the evidence is based on prospective observational studies/registries. As the observational studies/registries do not involve a control arm, they cannot definitively evaluate the true impact of RSV prophylaxis as documented in the placebo-controlled randomized trials \[[@CR23], [@CR24]\]. In addition, the populations in these cohorts may be variable, as enrollment is based on country-specific pediatric prophylaxis guidelines and the data reflect the way in which health care providers use palivizumab in the real world. Finally, RSV hospitalization detection rates are influenced by the hospitalization/ICU threshold changes over time, changes in bronchiolitis diagnosis over time, the type of samples collected, and the type of tests conducted.

Conclusion {#Sec17}
==========

We conducted a systematic review of published palivizumab RCT results, prospective, non-comparative clinical trial results, and published observational data to describe the safety, efficacy, and effectiveness of palivizumab for reducing the risk of serious RSV LRTI disease in high-risk infants and children. Since approval in 1998, palivizumab has been used in more than 80 countries for the passive prevention of serious RSV disease in high-risk children, and the patient exposure to palivizumab has been over 3.2 million seasonal courses of therapy (data on file, AbbVie). Compared with placebo, the efficacy of palivizumab, as measured by a reduction in the rate of RSV-related hospitalization, depends on the high-risk groups assessed and varied from 39% to 82% in subjects with BPD and CHD and premature infants (≤35 weeks GA) \[[@CR23], [@CR24], [@CR30]\]. A meta-analysis of the RSV-related hospitalization rate from 5 randomized, placebo-controlled trials yielded an overall OR of 0.41 (95% CI, 0.31--0.55) in favor of palivizumab prophylaxis over placebo (*P* \< 0.00001). Palivizumab has shown an acceptable safety profile, including a low incidence of anti-palivizumab antibodies in children with BPD, infants with a history of prematurity, and children with hemodynamically significant CHD.
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